Search Results - "Scipione, C"

  • Showing 1 - 9 results of 9
Refine Results
  1. 1

    Characterization of the I4399M variant of apolipoprotein(a): implications for altered prothrombotic properties of lipoprotein(a) by Scipione, C. A., McAiney, J. T., Simard, D. J., Bazzi, Z. A., Gemin, M., Romagnuolo, R., Macrae, F. L., Ariëns, R. A., Hegele, R. A., Auld, J., Gauld, J. W., Boffa, M. B., Koschinsky, M. L.

    Published in Journal of thrombosis and haemostasis (01-09-2017)
    “…Essentials Elevated lipoproteinp(a) is an independent and causal risk factor for atherothrombotic diseases. rs3798220 (Ile/Met substitution in apo(a)…”
    Get full text
    Journal Article
  2. 2

    Identification of human thrombin-activatable fibrinolysis inhibitor in vascular and inflammatory cells by Lin, J H H, Garand, M, Zagorac, B, Schadinger, S L, Scipione, C, Koschinsky, M L, Boffa, M B

    Published in Thrombosis and haemostasis (01-06-2011)
    “…TAFI (thrombin-activatable fibrinolysis inhibitor) is a carboxypeptidase zymogen originally identified in plasma. The TAFI pathway helps to regulate the…”
    Get more information
    Journal Article
  3. 3

    Pro-inflammatory cytokines reduce human TAFI expression via tristetraprolin-mediated mRNA destabilisation and decreased binding of HuR by Komnenov, D, Scipione, C A, Bazzi, Z A, Garabon, J J W, Koschinsky, M L, Boffa, M B

    Published in Thrombosis and haemostasis (01-08-2015)
    “…Thrombin activatable fibrinolysis inhibitor (TAFI) is the zymogen form of a basic carboxypeptidase (TAFIa) with both anti-fibrinolytic and anti-inflammatory…”
    Get more information
    Journal Article
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9